The scope of this report covers therapeutics used in the treatment of communicable diseases. The report highlights the current and future market potential of communicable diseases therapeutics and provides a detailed analysis of the competitive environment, regulations, epidemiology of communicable diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.
The market is expected to grow during the forecast period owing to rising prevalence of sexually transmitted diseases, growing awareness regarding communicable diseases, development of novel therapies, and growing public and private partnership for research of new therapies.
The global communicable disease market is segmented based on disease indication and region.
North America is estimated to have the highest market share and the Asia-Pacific region is anticipated to have the highest growth rate during the forecast period. The increase in health care expenditure in the Asia-Pacific market, growing research and development activities, and increase in the prevalence of STDs, HIV, and infectious diseases coupled with growing government initiative in creating awareness regarding communicable disease are the major factors augmenting the growth of communicable disease market in the Asia-Pacific region.
The report details market shares of communicable diseases based on different disease indication. Based on disease indication the market is segmented into HIV, Hepatitis B&C, Herpes Simplex Virus, Influenza, Malaria, Tuberculosis, and Others.
The Report Includes:
Detailed overview of the global market for communicable diseases within the healthcare industry
Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
The regional analysis of the communicable disease market, covering North America, Europe, Asia-Pacific, South America, and Middle East & Africa
A look at the government regulations pertaining to drug developments for communicable diseases and pipeline analysis covering ongoing clinical trials and promising forthcoming therapies in late-stage
Discussion of the competitive landscape, mergers and acquisitions of companies to enhance their product portfolio, and future commercial marketplace
Comprehensive company profiles of major market players, including Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, Novartis AG and Pfizer Inc.
Key Topics Covered:
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Custom Research
Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Disease Overview
HIV
HIV Timeline and Milestones
HIV Life Cycle: Treatment and Mechanism of Action
HIV Prophylaxis
Epidemiology
Chlamydia
Epidemiology
Genital Herpes
Epidemiology
Gonorrhea
Epidemiology
Hepatitis A, B and C
Epidemiology
HPV
Syphilis
Epidemiology
Malaria
Incidence and Geographical Distribution
Tuberculosis
Incidence and Geographical Distribution
Influenza
Incidence and Mortality
Trichomoniasis
Scabies
Bacterial Vaginosis
Candidiasis
Chancroid (Venereal Ulcers)
Pediculosis Pubis
Chapter 4 Market Dynamics
Market Drivers
Regional Awareness Program for Communicable Diseases
Development of Novel Therapies
Public-Private Partnership
Global Program to Counter HIV
Increasing Prevalence of Communicable Diseases
Market Restraints
Social Stigma Associated with STD
High Cost of Treatment
Underestimating the Risk of Contracting the Disease
Lack of Prenatal Screenings for STD
Chapter 5 Market Breakdown by Disease Type
Global Market for Communicable Disease, by Disease Indication
HIV
Hepatitis B&C
Herpes Simplex Virus
Influenza
Malaria
Tuberculosis
Others
Chapter 6 Market Breakdown by Region
Global Market for Communicable Disease, by Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Middle East & Africa
Chapter 7 Pipeline Analysis
Overview
Hepatitis B and Hepatitis C
Herpes Simplex Virus
HIV/AIDS
Influenza A and Influenza B
Respiratory Syncytial Virus
Malaria
Tuberculosis
MERS
Hemorrhagic Fevers
Dengue
Ebola
Lassa fever
Marburg
Yellow Fever
Zika
Chapter 8 Regulation and Reimbursement
Regulations
U.S.
Europe
Japan
China
Pricing and Reimbursement
U.S.
Europe
Japan
Chapter 9 Competitive Landscape
Sexually Transmitted Disease Therapeutics: Global Competitor Analysis
Influenza Therapeutics: Global Competitor Analysis
On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system...
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...